Acute Myeloid Leukemia Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Acute Myeloid Leukemia Market is segmented by chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, hormonal therapy, and other chemotherapies) and geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report offers the value in (USD million) for the above segments.

Acute Myeloid Leukemia Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Acute Myeloid Leukemia Market Size

Acute Myeloid Leukemia Market Summary
Study Period 2021 - 2030
Market Size (2025) USD 2.02 Billion
Market Size (2030) USD 3.27 Billion
CAGR (2025 - 2030) 10.15 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Acute Myeloid Leukemia Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Acute Myeloid Leukemia Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Acute Myeloid Leukemia Market Analysis

The Acute Myeloid Leukemia Market size is estimated at USD 2.02 billion in 2025, and is expected to reach USD 3.27 billion by 2030, at a CAGR of 10.15% during the forecast period (2025-2030).

The COVID-19 pandemic has significantly impacted the Acute Myeloid Leukemia market trends. Cancer treatments such as chemotherapy and immune suppressants damage the patient's immune system. This weakened immune system of the target population is expected to create a risk of COVID-19 infection. Various research was conducted to find the impact of COVID-19 on AML patients, influencing the Acute Myeloid Leukemia therapeutics market.

Furthermore, according to an article published by the American Society of Hematology, in January 2022, due to anticipated shortfalls in blood bank supplies during the COVID-19 pandemic, blood transfusion thresholds were lowered while taking into account significant local/regional variability. Patients who tested positive for COVID-19 had their treatment delayed. Since newly discovered AML is a treatment-emergent, intensive induction chemotherapy was made available to eligible AML patients. Thus, the increased risk for AML during a pandemic and the shortage of other treatment modalities are expected to drive the demand for AML drugs, impacting the Leukemia therapeutics market.

The key factors propelling the growth of the Acute Myeloid Leukemia therapeutics market are the high incidence and prevalence of Acute Myeloid Leukemia, advancements in pharmacology and molecular biology to promote drug development, and increasing investments in research and development by pharmaceutical companies. According to the American Cancer Society, it is estimated that there will be 60,650 new leukemia cancer cases, of which 24,000 are expected to die in 2022 in the US. In addition, according to the same source, 20,050 new cases of Acute Myeloid Leukemia (AML) are estimated in 2022 in the US. It will lead to increased adoption of AML therapies. The rising prevalence of AML in developed countries such as the US is expected to drive the Acute Myeloid Leukemia treatment market's growth.

Furthermore, with the rising investment in research and development and the expansion of the Acute Myelocytic Leukemia pipeline drugs market, there is an increasing number of clinical trials conducted to demonstrate the effectiveness of the drugs. It is expected to drive the market over the forecast period. For instance, according to the United States National Library of Medicine, a study titled 'Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs. Physician's Choice in Newly Diagnosed FLT3-ITD+ AML (Q-SOC)' is in Phase III of clinical trials. The study was estimated to start in November 2021 and be complete in March 2025.

Thus, the abovementioned factors are impacting the growth of the Acute Myeloid Leukemia market. However, stringent regulations on drugs and complications related to chemotherapy are the factors expected to restrain the market growth.

Acute Myeloid Leukemia Industry Overview

The Acute Myeloid Leukemia market, a significant part of the Blood Cancer therapeutics market, is consolidated in nature due to the presence of a few companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known, including Novartis AG, Teva Pharmaceuticals, Pfizer, Bristol Myers Squibb, and Sanofi-Aventis (Genzyme Corporation), among others.

Acute Myeloid Leukemia Market Leaders

  1. Pfizer Inc.

  2. Novartis AG

  3. Sanofi-Aventis (Genzyme Corporation)

  4. Otsuka holdings co., ltd.

  5. Bristol Myers Squibb

  6. *Disclaimer: Major Players sorted in no particular order
Acute Myeloid Leukemia Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Acute Myeloid Leukemia Market News

  • January 2022- Oncolyze announced the receival of FDA Orphan Drug Designation for OM-301 to treat acute myeloid leukemia (AML).
  • December 2021- the European Commission granted Orphan Drug Designation to SNDX-5613, a highly selective oral menin inhibitor, to treat acute myeloid leukemia (AML) developed by Syndax Pharmaceuticals Inc.

Acute Myeloid Leukemia Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 High Incidence and Prevalence of Acute Myeloid Leukemia
    • 4.2.2 Advancement in Pharmacology and Molecular Biology to Promote Drug Development
    • 4.2.3 Increasing Investments in Research and Development
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulations on Drugs
    • 4.3.2 Complications Related to Chemotherapy
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 Chemotherapy
    • 5.1.1 Cytarabine
    • 5.1.2 Anthracycline Drugs
    • 5.1.3 Alkylating Agents
    • 5.1.4 Anti-metabolites
    • 5.1.5 Tyrosine Kinase Inhibitors
    • 5.1.6 Hormonal Therapy
    • 5.1.7 Other Chemotherapies
  • 5.2 Geography
    • 5.2.1 North America
    • 5.2.1.1 United States
    • 5.2.1.2 Canada
    • 5.2.1.3 Mexico
    • 5.2.2 Europe
    • 5.2.2.1 Germany
    • 5.2.2.2 United Kingdom
    • 5.2.2.3 France
    • 5.2.2.4 Italy
    • 5.2.2.5 Spain
    • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
    • 5.2.3.1 China
    • 5.2.3.2 Japan
    • 5.2.3.3 India
    • 5.2.3.4 Australia
    • 5.2.3.5 South Korea
    • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East & Africa
    • 5.2.4.1 GCC
    • 5.2.4.2 South Africa
    • 5.2.4.3 Rest of Middle East & Africa
    • 5.2.5 South America
    • 5.2.5.1 Brazil
    • 5.2.5.2 Argentina
    • 5.2.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bristol-Myers Squibb Company (Celgene Corporation)
    • 6.1.2 Novartis AG
    • 6.1.3 Genmab AS
    • 6.1.4 Otsuka Holdings Co. Ltd
    • 6.1.5 Sanofi-Aventis (Genzyme Corporation)
    • 6.1.6 Teva Pharmaceutical (Cephalon Inc.)
    • 6.1.7 Pfizer Inc.
    • 6.1.8 F. Hoffmann-La Roche Ltd
    • 6.1.9 Sunesis Pharmaceuticals Inc.
    • 6.1.10 Astellas Pharma
    • 6.1.11 Oncolyze Inc.
    • 6.1.12 Syndax Pharmaceuticals Inc.
    • 6.1.13 AbbVie Inc.
    • 6.1.14 Amgen Inc.
    • 6.1.15 Agios Pharmaceuticals Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Acute Myeloid Leukemia Industry Segmentation

As per the scope of this report, acute myeloid leukemia is also known as acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, or acute non-lymphocytic leukemia. In acute myeloid leukemia, abnormal white blood cells are rapidly collected in the bone marrow and disturb the production of normal blood cells.

The Acute Myeloid Leukemia Market is segmented by chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, hormonal therapy, and other chemotherapies) and geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value in (USD million) for the above segments.

Chemotherapy Cytarabine
Anthracycline Drugs
Alkylating Agents
Anti-metabolites
Tyrosine Kinase Inhibitors
Hormonal Therapy
Other Chemotherapies
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Acute Myeloid Leukemia Market Research FAQs

How big is the Acute Myeloid Leukemia Market?

The Acute Myeloid Leukemia Market size is expected to reach USD 2.02 billion in 2025 and grow at a CAGR of 10.15% to reach USD 3.27 billion by 2030.

What is the current Acute Myeloid Leukemia Market size?

In 2025, the Acute Myeloid Leukemia Market size is expected to reach USD 2.02 billion.

Who are the key players in Acute Myeloid Leukemia Market?

Pfizer Inc., Novartis AG, Sanofi-Aventis (Genzyme Corporation), Otsuka holdings co., ltd. and Bristol Myers Squibb are the major companies operating in the Acute Myeloid Leukemia Market.

Which is the fastest growing region in Acute Myeloid Leukemia Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Acute Myeloid Leukemia Market?

In 2025, the North America accounts for the largest market share in Acute Myeloid Leukemia Market.

What years does this Acute Myeloid Leukemia Market cover, and what was the market size in 2024?

In 2024, the Acute Myeloid Leukemia Market size was estimated at USD 1.81 billion. The report covers the Acute Myeloid Leukemia Market historical market size for years: 2021, 2022, 2023 and 2024. The report also forecasts the Acute Myeloid Leukemia Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Acute Myeloid Leukemia Industry Report

The Acute Myeloid Leukemia Market is segmented by chemotherapy and geography. The report offers value for various chemotherapy treatments and regions. This market research is crucial for understanding market size, market share, and market analysis. The industry report provides a comprehensive market forecast and industry overview. Market trends and market growth are analyzed to predict future industry sales and market outlook.

Industry reports indicate significant market segmentation and market value. The market data and market review highlight the importance of industry statistics and industry trends. Market leaders and research companies contribute to the industry research, offering insights into market predictions and market overview.

The industry analysis includes a detailed industry outlook and industry information. The market forecast is essential for understanding the market growth rate and market predictions. The report example and report pdf provide a clear market review, emphasizing the importance of market value and industry statistics.

This industry report serves as a valuable resource for understanding the market outlook and market segmentation. The market data and industry trends are crucial for predicting future market growth and industry sales. The report pdf offers a comprehensive overview, making it an essential tool for market research and industry analysis.